Stockscreener 앱 받기
32.64
1.33%
0.43
시간 외 거래:
32.80
0.16
+0.49%
Oruka Therapeutics Inc 주식(ORKA)의 최신 뉴스
Candriam S.C.A. Buys 250,296 Shares of Oruka Therapeutics, Inc. $ORKA - MarketBeat
Will Oruka Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Action & Accurate Buy Signal Alerts - mfd.ru
Is Oruka Therapeutics Inc. stock a contrarian buy2025 Investor Takeaways & Expert Curated Trade Setup Alerts - mfd.ru
Oruka Therapeutics to Participate in Multiple Upcoming Conferences - The Manila Times
Oruka Therapeutics präsentiert sich auf mehreren internationalen Biotech-Konferenzen - Longbridge
Dow Update: What is Oruka Therapeutics Incs book value per share2025 Retail Activity & Verified Swing Trading Watchlists - baoquankhu1.vn
Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy - TipRanks
How Oruka Therapeutics Inc. stock performs in high volatility marketsJuly 2025 EndofMonth & Long Hold Capital Preservation Plans - mfd.ru
Investment Review: Will Oruka Therapeutics Inc outperform tech stocks2025 Risk Factors & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Down 31.3% in January - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Oruka Therapeutics, Inc. (ORKA) Stock Report: Biotechnology Pioneer Poised for 57.87% Upside - DirectorsTalk Interviews
Portfolio Update: Is Global Blue Group Holding AG Equity Warrant stock a top performer YTDQuarterly Growth Report & Long Hold Capital Preservation Plans - baoquankhu1.vn
How cyclical is Oruka Therapeutics Incs revenue streamWeekly Investment Recap & Safe Capital Growth Stock Tips - baoquankhu1.vn
How Early ORKA-002 Dosing Data At Oruka Therapeutics (ORKA) Has Changed Its Investment Story - simplywall.st
H.C. Wainwright Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛
Oruka Therapeutics (NASDAQ:ORKA) Shares Gap DownHere's What Happened - MarketBeat
Market Outlook: Does Oruka Therapeutics Inc stock have upside surprise potential2025 Market Overview & Stock Portfolio Risk Management - baoquankhu1.vn
Fed Meeting: Will Oruka Therapeutics Inc outperform tech stocksJuly 2025 Reactions & Entry Point Confirmation Signals - baoquankhu1.vn
RSI Check: Can GLPG outperform under higher oil pricesJuly 2025 Highlights & Daily Market Momentum Tracking - baoquankhu1.vn
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week HighWhat's Next? - MarketBeat
Gains Report: Will Oruka Therapeutics Inc benefit from AI trendsGold Moves & Reliable Momentum Entry Alerts - baoquankhu1.vn
Aug Opening: Will ARTV outperform the market in YEAR2025 Major Catalysts & Low Drawdown Trading Techniques - baoquankhu1.vn
Assessing Oruka Therapeutics (ORKA) Valuation After Encouraging ORKA 002 Phase 1 Trial Results - Sahm
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Update - MarketBeat
Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock - MarketBeat
Oruka Therapeutics stock hits 52-week high at 32.65 USD By Investing.com - Investing.com Nigeria
Oruka Therapeutics (ORKA) Is Up 23.1% After Extended-Dosing IL-17 Data for ORKA-002What's Changed - Sahm
Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month HighHere's Why - MarketBeat
Oruka Therapeutics stock hits 52-week high at 32.65 USD - Investing.com
Pullback Watch: What is Oruka Therapeutics Incs book value per shareJuly 2025 Review & Fast Entry Momentum Alerts - baoquankhu1.vn
Oruka Therapeutics (ORKA) Price Target Increased by 12.54% to 56.44 - Nasdaq
Clear Street raises Oruka Therapeutics stock price target on promising drug data - Investing.com Canada
Oruka reports positive interim data for ORKA-002 in Phase 1 trial - Investing.com Nigeria
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001 - Dermatology Times
BTIG Research Issues Positive Forecast for Oruka Therapeutics (NASDAQ:ORKA) Stock Price - MarketBeat
Oruka reports positive interim data for ORKA-002 in Phase 1 trial By Investing.com - Investing.com South Africa
Oruka Therapeutics, Inc. Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of Everlong-B Trial of ORKA-001 - marketscreener.com
Earnings Risk: Is OPFI affected by consumer sentimentJuly 2025 Highlights & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from Analysts at UBS Group - Defense World
Aug Outlook: Why Oruka Therapeutics Inc. stock is favored by top institutions2025 Retail Activity & Real-Time Volume Spike Alerts - Улправда
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: Unpacking a 97.60% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Oruka Therapeutics (NASDAQ:ORKA) Rating Increased to Strong-Buy at UBS Group - MarketBeat
ORKA-001 psoriasis trial: Fresh phase 2 update and what it means for investors - MSN
Does UBS’s New Coverage Reframe Oruka Therapeutics (ORKA) as a Peptide Platform, Not Just a Biotech? - Sahm
How buybacks impact Oruka Therapeutics Inc. stock valueJuly 2025 Macro Moves & Risk Controlled Swing Alerts - ulpravda.ru
Can Oruka Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - Улправда
Will Oruka Therapeutics Inc. (HQ1) stock top growth indexes2025 Market WrapUp & Precise Swing Trade Entry Alerts - ulpravda.ru
Why Oruka Therapeutics Inc. stock is a must watch in 2025Earnings Beat & AI Powered Market Entry Strategies - Улправда
Is Oruka Therapeutics Inc. (HQ1) stock undervalued historicallyJuly 2025 Technicals & Reliable Price Breakout Alerts - Улправда
1.24%
0.19%
자본화:
|
볼륨(24시간):